Johnson & Johnson Interest Expense 2011-2026 | JNJ

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Johnson & Johnson

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
7.21 B	-4.69 B	-6.63 B	183 M	201 M	-	318 M	1 B	934 M	552 M	-	533 M	482 M	532 M	455 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
7.21 B	-6.63 B	82.8 M

Quarterly Interest Expense Johnson & Johnson

2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
478 M	-107 M	7.32 B	-1.8 B	-653 M	-2.4 B	-499 M	384 M	212 M	-	51 M	38 M	10 M	-	20 M	40 M	63 M	-	44 M	45 M	25 M	-	48 M	83 M	102 M	-	243 M	253 M	259 M	-	229 M	227 M	204 M	-	192 M	190 M	160 M	-	123 M	131 M	138 M	-	130 M	128 M	136 M	-	105 M	118 M	125 M	-	135 M	143 M	147 M	-	134 M	129 M	125 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
7.32 B	-2.4 B	165 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
Apellis Pharmaceuticals APLS	-133 K	$ 20.41	-1.4 %	$ 2.57 B	USA
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Axsome Therapeutics AXSM	-15.9 M	$ 165.07	-0.79 %	$ 8.21 B	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
AbCellera Biologics ABCL	-2.71 M	$ 3.76	-1.7 %	$ 1.12 B	Canada
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Capricor Therapeutics CAPR	399 K	$ 26.36	-1.82 %	$ 706 M	USA
Certara CERT	6.34 M	$ 7.24	2.62 %	$ 1.16 B	USA
Codexis CDXS	-10.4 M	$ 1.01	-0.98 %	$ 74.1 M	USA
AgeX Therapeutics AGE	4.9 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Catalyst Pharmaceuticals CPRX	25.7 M	$ 23.77	-0.46 %	$ 2.91 B	USA
Agenus AGEN	1.26 M	$ 3.27	-2.09 %	$ 1.17 M	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Agios Pharmaceuticals AGIO	1.96 M	$ 28.85	-1.2 %	$ 1.67 B	USA
Champions Oncology CSBR	73 K	$ 5.98	-1.48 %	$ 81.7 M	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Cellectis S.A. CLLS	371 K	$ 3.71	-2.43 %	$ 116 M	France
Alector ALEC	13.2 M	$ 2.13	-3.39 %	$ 219 M	USA
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA
Aileron Therapeutics ALRN	685 K	-	10.36 %	$ 9.8 M	USA
Altimmune ALT	48 K	$ 4.22	1.32 %	$ 300 M	USA
AlloVir ALVR	1.19 M	-	4.14 %	$ 49.1 M	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Amarin Corporation plc AMRN	7 K	$ 14.3	2.66 %	$ 5.93 B	Irlanda
AbbVie ABBV	2.89 B	$ 233.44	-0.33 %	$ 413 B	USA